Menu
GWAS Study

Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2.

Ellinghaus E, Ellinghaus D, Stuart PE et al.

20953188 PubMed ID
GWAS Study Type
14524 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

EE
Ellinghaus E
ED
Ellinghaus D
SP
Stuart PE
NR
Nair RP
DS
Debrus S
RJ
Raelson JV
BM
Belouchi M
FH
Fournier H
RC
Reinhard C
DJ
Ding J
LY
Li Y
TT
Tejasvi T
GJ
Gudjonsson J
SS
Stoll SW
VJ
Voorhees JJ
LS
Lambert S
WS
Weidinger S
EB
Eberlein B
KM
Kunz M
RP
Rahman P
GD
Gladman DD
GC
Gieger C
WH
Wichmann HE
KT
Karlsen TH
MG
Mayr G
AM
Albrecht M
KD
Kabelitz D
MU
Mrowietz U
AG
Abecasis GR
EJ
Elder JT
SS
Schreiber S
WM
Weichenthal M
FA
Franke A
Chapter II

Abstract

Summary of the research findings

Psoriasis is a multifactorial skin disease characterized by epidermal hyperproliferation and chronic inflammation, the most common form of which is psoriasis vulgaris (PsV). We present a genome-wide association analysis of 2,339,118 SNPs in 472 PsV cases and 1,146 controls from Germany, with follow-up of the 147 most significant SNPs in 2,746 PsV cases and 4,140 controls from three independent replication panels. We identified an association at TRAF3IP2 on 6q21 and genotyped two SNPs at this locus in two additional replication panels (the combined discovery and replication panels consisted of 6,487 cases and 8,037 controls; combined P = 2.36 × 10⁻¹⁰ for rs13210247 and combined P = 1.24 × 10⁻¹⁶ for rs33980500). About 15% of psoriasis cases develop psoriatic arthritis (PsA). A stratified analysis of our datasets including only PsA cases (1,922 cases compared to 8,037 controls, P = 4.57 × 10⁻¹² for rs33980500) suggested that TRAF3IP2 represents a shared susceptibility for PsV and PsA. TRAF3IP2 encodes a protein involved in IL-17 signaling and which interacts with members of the Rel/NF-κB transcription factor family.

472 European ancestry cases, 1,146 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

14524
Total Participants
GWAS
Study Type
Yes
Replicated
2,668, European ancestry cases, 762 French Canadian founder population cases, 2,585 cases, 3,485 European ancestry controls, 994 French Canadian founder population controls, 2,412 controls
Replication Participants
European
Ancestry
U.S., Canada, Germany
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.